Genmab — Maj 2019

StockBull

Syns da Sydbank er havlnegative m.h.t deres nettoresultat på 1.705 og 2.111 til forskel fra JPM som har 1.823 og 2.562 og konsensus endnu højere

jkj

ved vi hvad konsensus forventning er idag ?

jkj

Det er langt fra syd bank estimat på 588 / 8 mail dkr. som jeg syndes ikke virker urealistisk.

Helge_LarsenPI-redaktør

Helge_LarsenPI-redaktør

(borsen.dk)

E_L

Horizon Pharma is now Horizon Therapeutics plc. lol. Anyway, Continue to Expect Mid-2019 U.S. Biologics License Application (BLA) Submission for Teprotumumab . ( Teprotumumab has received Breakthrough Therapy, Orphan Drug and Fast Track designations from the FDA. If approved, teprotumumab would be the first and only approved treatment for active TED.) http://ir.horizontherapeutics.com/news-releases/news-release-details/horizon-therapeutics-plc-reports-strong-first-quarter-2019

Plimsoller

@ E L thank you. That is really good news.

peter12

Marshall Wace LLP holds a short position at 0.54 % in shares issued by Genmab A/S

E_L

New trial : Daratumumab, Ixazomib, & Dexamethasone With or Without Bortezomib in Patients With Newly Diagnosed Multiple Myeloma (DeRIVE) - https://clinicaltrials.gov/ct2/show/NCT03942224

peter12

De har nok skumle planer ...

E_L

I actually thought Ixazomib and bortezomib are sort of similar, both proteasome inhibitors , did not expect them to be used together

Plimsoller

(borsen.dk)

ienk1

Marshall Wace LLP has reduced his short position to 303580 shares issued by Genmab A/S 14/02 2019

Bulder

E L, you can see the explanation in experimental arm II. They don't get isa and bor at the same time.

E_L

ok, thks, i see it now

Bulder

+6 kroner på en lukkeauktion. Det er vist rekord.

Helge_LarsenPI-redaktør

E_L

jkj

nøgletal lidt dårligere end forventet

jkj

Den skal tales godt op til q&A ellers er der ingen belønning.